BK and JC polyomaviruses (BKPyV, JCPyV) cause disease in immunocompromised persons. Both are double-stranded DNA viruses in the family *Polyomaviridae*. Seven additional human polyomaviruses were discovered during 2007--2011: KI polyomavirus (KIPyV) ([@R1]), WU polyomavirus (WUPyV) ([@R2]), Merkel cell polyomavirus (MCPyV) ([@R3]), human polyomavirus 6 (HPyV6) ([@R4]), human polyomavirus 7 (HPyV7) ([@R4]), trichodysplasia spinulosa-associated polyomavirus (TSPyV) ([@R5]), and human polyomavirus 9 (HPyV9) ([@R6]).

The 7 novel polyomaviruses have been detected in various specimen types; detection has been extensively reviewed for KIPyV, WUPyV, and MCPyV ([@R7]). Polyomaviruses HPyV6, HPyV7, TSPyV, and HPyV9 have been detected in skin ([@R4],[@R5],[@R8]); TSPyV and HPyV9 have also been detected in urine, and HPyV9 was detected in serum ([@R6]). However, only 2 of these recently identified viruses have been specifically implicated in human diseases; MCPyV is associated with Merkel cell carcinoma ([@R3]), and TSPyV has been linked to trichodysplasia spinulosa ([@R5]). Immunosuppression is a likely cofactor in both diseases. The potential pathogenicity of the other 5 novel polyomaviruses is unknown. As a first step toward exploring their disease potential, we sought to define their prevalence in immunocompromised transplant recipients. To this end, we established a longitudinal cohort of children undergoing transplantation at St. Louis Children's Hospital, St. Louis, Missouri, USA.

The Study
=========

We recruited 32 patients who were scheduled to receive transplants (2 lung, 11 liver, 5 heart, 2 kidney, 1 liver/lung, and 11 bone marrow transplants) during October 2008--April 2010. The Human Research Protection Office of Washington University in St. Louis approved this study. The mean age of enrolled patients was 5.8 years, and the median age was 3.1 years. Thirty patients received transplants and were studied for 1 year after transplantation. We collected 716 clinical specimens (160 nasopharyngeal swab, 169 urine, 122 fecal, 265 plasma) during 265 patient visits. We collected 298 specimens from patients during symptomatic episodes, which were defined as having [\>]{.ul}1 of the following: fever, respiratory symptoms, or gastrointestinal symptoms. We collected clinical data using a questionnaire and the medical records.

Fecal material was diluted 1:6 in phosphate-buffered saline and filtered through 0.45-μm membranes. For all specimens, we extracted total nucleic acids using an Ampliprep Cobas extractor (Roche, Branchburg, NJ, USA). We used published real-time PCRs for WUPyV ([@R9]), KIPyV ([@R9]), TSPyV ([@R5]), MCPyV ([@R10]), BKPyV ([@R11]), and JCPyV ([@R12]) ([Table 1](#T1){ref-type="table"}). We developed assays for HPyV6, HPyV7, and HPyV9 using Primer Express software (Applied Biosystems, Carlsbad, CA, USA) ([Table 1](#T1){ref-type="table"}). To assess the performance of each assay, we used serial dilutions (5 to 5 × 10^6^ copies/reaction) of a plasmid containing the target sequence. All 3 assays demonstrated a sensitivity of ≈5 copies/reaction and yielded linear curves with R^2^ values \>0.99.

###### Real-time PCR assays to detect human polyomaviruses in children undergoing transplants, United States, 2008--2010\*

  Virus                                       Target   Primers, 5′ → 3′                       Probe, 5′ → 3′
  ------------------------------------------- -------- -------------------------------------- ------------------------------------------------------------
  WUPyV                                       NCCR     WU-C-4824-F: GGCACGGCGCCAACT           WU-C-4861-TM: FAM-TGCCATACCAACACAGCTGCTGAGC-TAMRA-3′
  WU-C-4898-R: CCTGTTGTAGGCCTTACTTACCTGTA                                                     
  KIPyV                                       LTAg     KI-B-4603-F: GAATGCATTGGCATTCGTGA      KI-B-4632-TM: FAM-TGTAGCCATGAATGCATACATCCCACTGC-TAMRA
  KI-B-4668-R: GCTGCAATAAGTTTAGATTAGTTGGTGC                                                   
  TSPyV                                       LTAg     LTF: TGTGTTTGGAAACCAGAATCATTTG         LTP: FAM-TTCTTCTTCCTCCTCATCCTCCACCTCAAT-TAMRA
  LTR: TGCTACCTTGCTATTAAATGTGGAG                                                              
  MCPyV                                       LTAg     LT.1F: CCACAGCCAGAGCTCTTCCT            LT probe: FAM-TCCTTCTCAGCGTCCCAGGCTTCA-TAMRA
  LT.1R: TGGTGGTCTCCTCTCTGCTACTG                                                              
  HPyV6                                       VP1      ES011F: GCCTGGAAGGGCCTAGTAAAG          ES024: FAM-ACCAACCATCTGTTGCAGGCATTAAAGCTA-TAMRA
  ES012R: ATTGGCAGCTGTAACTTGTTTTCTG                                                           
  HPyV7                                       VP1      ES017F: GGTCCAGGCAATACTGATGTAGCTA      ES025: FAM-CCTGCAAGCCCTCAGAAAGCAAGTAAATG-TAMRA
  ES018R: TCTGCAACCCAGAGCTCTACTG                                                              
  HPyV9                                       LTAg     ES026F: GAAGACCCTGATCCTGAGGAAGA        ES031: FAM-TGGATCATCCCAGAGTTCATTTACCTGCA-TAMRA
  ES027R: CTCTGGAGTATTAGGTTCAGGCTTCT                                                          
  BKPyV                                       LTAg     BK-Deg-F: AGCAGGCAAGRGTTCTATTACTAAAT   Bk-Deg-P: FAM-AAGACCCTAAAGACTTTCCYTCTGATCTACACCAGTTT-TAMRA
  BK-Deg-R: GARGCAACAGCAGATTCYCAACA                                                           
  JCPyV                                       VP2/3    JL1 (F): AAGGGAGGGAACCTATATTTCTTTTG    JL1 (P): FAM-CTCATACACCCAAAGTATAGATGATGCAGACAGCA-TAMRA
  JL1 (R): TCTAGCCTTTGGGTAACTTCTTGAA                                                          

\*WUPyV, WU polyomavirus; NCCR, non-coding control region; KIPyV, KI polyomavirus; LTAg, large T antigen; TSPyV, trichodysplasia spinulosa polyomavirus; MCPyV, Merkel cell polyomavirus; HPyV, human polyomavirus; VP, virion protein; BKPyV, BK polyomavirus; JCPyV, JC polyomavirus.

Each of the 25-μl quantitative PCRs included 5 μL of extracted sample, 12.5 pmol of each primer, and 4 pmol of probe. The MCPyV primers and probe were used as described ([@R10]). We tested samples in a 96-well plate format, with 8 water negative controls and 1 positive control/plate. Reactions were cycled as recommended using either an ABI 7500 real-time thermocycler (Applied Biosystems) or a CFX96 real-time thermocycler (BioRad, Hercules, CA, USA). The threshold of all plates was set at a standard value, and samples were counted as positive if their cycle threshold was \<37.00.

All 716 specimens were tested for each virus ([Table 2](#T2){ref-type="table"}). The most frequently detected virus was BKPyV, which was found primarily in urine as expected. JCPyV was detected in 1 plasma sample. HPyV6, HPyV7, MCPyV, and TSPyV were detected in specimen types not previously reported. HPyV6 and TSPyV were detected in fecal samples and nasopharyngeal swab samples, and HPyV7 was detected in a nasopharyngeal swab and urine. One fecal sample was positive for MCPyV. Because HPyV6, HPyV7, and MCPyV have been previously detected in skin, we cannot rule out the possibility that their presence in specimens could have been caused by shedding from skin.

###### Polyomaviruses detected among specimens from children undergoing transplants, United States, 2008--2010\*

  Virus   Specimen type   Transplant   C~t~    Patient ID   Date of collection, time elapsed from transplant
  ------- --------------- ------------ ------- ------------ --------------------------------------------------
  HPyV6   Feces           BMT          32.19   3011         2012 Jun 06, 1 mo after transplant
  HPyV6   NP              Heart        36.13   4005         2010 Nov 25, 7 mo after transplant
  HPyV6   Feces           Lung         36.95   5001         2010 Aug 17, 1 mo after transplant
  HPyV7   NP              Liver        34.57   1002         2009 Jun 16, 7 mo after transplant
  HPyV7   Urine           Liver        36.54   1002         2009 Jul 15, 8 mo after transplant
  HPyV9   Urine           Liver        36.72   1009         2010 Feb 09, 1 wk after transplant
  KIPyV   NP              BMT          16.28   3001         2009 Jul 07, 3 mo after transplant
  KIPyV   NP              BMT          36.07   3001         2009 May 19, 1 mo after transplant
  KIPyV   NP              BMT          33.37   3008         2009 Nov 12, before transplant
  KIPyV   NP              BMT          31.04   3009         2010 Jul 30, 6 mo after transplant
  MCPyV   NP              BMT          36.29   3011         2010 Apr 15, before transplant
  MCPyV   Feces           BMT          34.56   3011         2010 Jul 02, 2 mo after transplant
  TSPyV   NP              Heart        32.98   4001         2009 May 29, 1 wk after transplant
  TSPyV   NP              Heart        30.74   4001         2009 Jun 18, 1 mo after transplant
  TSPyV   Feces           Heart        33.89   4001         2009 May 29, 1 wk after transplant
  WUPyV   NP              BMT          36.62   3005         2009 Jul 15, before transplant
  WUPyV   NP              BMT          28.81   3007         2009 Nov 06, 2 mo after transplant
  JCPyV   Plasma          BMT          36.12   3011         2010 Aug 24, 3 mo after transplant
  BKPyV   Urine           BMT          15.83   3010         2010 Apr 15, 1 mo after transplant
  BKPyV   Urine           Kidney       36.67   2022         2010 Jul 01, 10 mo after transplant
  BKPyV   Urine           BMT          30.80   3011         2010 Aug 24, 3 mo after transplant
  BKPyV   Urine           Heart        25.84   4001         2009 Aug 14, 2 mo after transplant
  BKPyV   Urine           Heart        35.89   4003         2009 Dec 23, 2 mo after transplant
  BKPyV   Urine           Heart        24.37   4001         2009 Sep 23, 4 mo after transplant
  BKPyV   Urine           Liver        28.56   1010         2009 Nov 23, 1 wk after transplant
  BKPyV   Urine           Lung         33.13   5002         2011 May 03, 1 year after transplant
  BKPyV   Urine           Lung         25.25   5002         2011 Feb 08, 10 mo after transplant
  BKPyV   Urine           Kidney       9.97    2002         2010 Mar 04, 6 mo after transplant
  BKPyV   Urine           BMT          30.10   3009         2010 Mar 05, 2 mo after transplant
  BKPyV   Urine           Liver        22.89   1001         2009 Jan 07, 3 mo after transplant
  BKPyV   Urine           Kidney       34.41   2002         2010 May 13, 8 mo after transplant
  BKPyV   NP              Kidney       35.93   2002         2010 Mar 04, 6 mo after transplant
  BKPyV   Feces           Kidney       33.15   2002         2010 Mar 04, 6 mo after transplant
  BKPyV   Feces           Liver        33.33   1001         2008 Dec18, 2 mo after transplant
  BKPyV   Feces           Liver        34.84   1001         2009 Jan 07, 3 mo after transplant

\*C~t~, cycle threshold; ID, identification; HPyV, human polyomavirus; BMT, bone marrow transplant; NP, nasopharyngeal; KIPyV, KI polyomavirus; MCPyV, Merkel cell polyomavirus; TSPyV, trichodysplasia spinulosa polyomavirus; WUPyV, WU polyomavirus; JCPyV, JC polyomavirus; BKPyV, BK polyomavirus

We collected 2 serial nasopharyngeal samples that were positive for KIPyV from patient 3001 ([Table 2](#T2){ref-type="table"}), a 1-year-old child who had received a bone marrow transplant as treatment for Fanconi anemia. The first sample, a nasopharyngeal swab obtained 1 month after transplant, had low levels of KIPyV. To determine the viral load of the second nasopharyngeal swab specimen collected 2 months later, we reanalyzed the sample in triplicate; on the basis of extrapolation of the standard curve run in parallel, we estimated the viral load to be 1.3 × 10^9^ genome copies/mL of nasopharyngeal swab transport media. This patient's course was complicated by graft-versus-host disease of the gut and skin, renal failure requiring dialysis, and recurrent pulmonary hemorrhage. The patient was critically ill and had experienced multiorgan failure at the time of the second sampling. Other microbiological test results were negative at that time, including PCR for Epstein-Barr virus, cytomegalovirus, human herpesvirus-6, and adenovirus in the blood; aspergillus antigen detection in blood; and bacterial cultures of blood, tracheal aspirate, urine, and peritoneal fluid. The fecal specimen collected at this time was negative for KIPyV; plasma and urine were not available for this study. The patient died of acute respiratory failure and extensive pulmonary hemorrhage 24 days after collection of this specimen. Despite the frequent detection of KIPyV in respiratory specimens, no studies have definitively linked infection with respiratory disease. Titers of KIPyV were high in the nasopharyngeal swab sample from this patient 3 weeks before respiratory failure. Although this observation does not necessarily implicate KIPyV infection as a contributing factor in the death of the patient, it suggests a poorly controlled KIPyV infection in the respiratory tract.

Three specimens collected from patient 4001, a 13-year-old heart transplant recipient, were positive for TSPyV ([Figure](#F1){ref-type="fig"}), but the patient did not have trichodysplasia spinulosa. At 1 week after transplant, the nasopharyngeal swab and fecal samples were positive for TSPyV. At 1 month after transplant, the nasopharyngeal swab sample was again positive for TSPyV, with a viral load of ≈2.3 × 10^4^ genome copies/mL of transport media. There is currently only 1 TSPyV sequence in GenBank (accession no. GU989205). We used 4 primer pairs to amplify the complete genome of TSPyV from the nasopharyngeal swab taken 1 month after transplant. PCR products were cloned, and the complete genome was sequenced to 3× coverage (GenBank accession no. JQ723730) and compared with the other TSPyV sequence. There were 5 nt substitutions: 3 in noncoding regions and 2 synonymous mutations.

![Samples tested for TSV (trichodysplasia spinulosa polyomavirus) during May--June 2009 from patient 4001, a 13-year-old heart transplant recipient at St. Louis Children's Hospital, St. Louis, Missouri, USA. Samples tested at each time point are indicated by white squares. Black squares represent positive samples. NP, nasopharyngeal.](12-0359-F){#F1}

Although serologic studies have demonstrated that ≈70% of adults in Europe have been infected by TSPyV ([@R13]), its mode of transmission is unknown. The detection of TSPyV in nasopharyngeal swab and fecal samples raises the possibility that it may be transmitted by a respiratory or fecal--oral route. Furthermore, in the current study, 2 sequential nasopharyngeal swab samples taken 20 days apart were positive for TSPyV, suggesting it may persist for extended periods in the respiratory tract, at least in immunosuppressed persons.

Conclusions
===========

Our goals were to establish a longitudinal repository of different specimens types from transplant recipients and to define the prevalence of polyomaviruses in these patients. We detected all 9 polyomaviruses in at least 1 specimen. Although the prevalence of each virus was generally low, TSPyV, HPyV6, HPyV7, and MCPyV were detected in specimen types not previously reported. These observations expand understanding of the recently identified polyomaviruses and the tissue and organ systems they may infect and suggest possible modes of transmission. Further studies to define their possible roles in human diseases are needed.
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